BIAL’s mission is to discover, develop and provide new therapeutic solutions within the area of Health. Today, BIAL is an innovative international pharmaceutical company with products available in more than 55 countries. The company is committed to making a contribution to improve human health and quality of life for people from all over the world. “Caring for your Health” is the Group’s motto, and strategic areas are Innovation, Internationalisation and Quality. Strongly committed to therapeutic innovation, and consistently investing more than 20% of its annual revenue in Research and Development (R&D), BIAL has established an ambitious R&D programme. Key focus areas for the Group are the neurosciences and cardiovascular. BIAL has launched eslicarbazepine acetate, an epilepsy drug, already available in the US and in several European countries. BIAL has also developed a Parkinson’s disease compound, opicapone, also commercialized in Europe. The company expects to introduce new medicines to the market over the next few years, strengthening its international presence.

NeuroDerm is a clinical-stage pharmaceutical company developing next-generation treatments for central nervous system (CNS) disorders that will make a clinically meaningful difference in patients’ lives. NeuroDerm’s technology enables new routes of administration for existing drugs that overcome their current deficiencies and achieve enhanced clinical efficacy.

Shionogi & Co., Ltd. engages in the research, development, supply, manufacture and sale of pharmaceutical products. Its products include prescription drugs, over-the-counter drugs, diagnostic regents, medical devices and others. The company was founded by Gisaburo Shiono on March 17, 1878 and is headquartered in Osaka, Japan.

SOM Biotech is a drug innovation company based on a pioneering AI-based drug discovery technology – SOM AI PRO -, that has built a robust pipeline focused mainly on Orphan CNS products with very high unmet need and blockbuster potential. SOM AI PRO has been validated with 2 successful Phase 2 trials (TTR Amyloidosis, Chorea in Huntington disease), and four programs are at the preclinical stage. SOM Biotech applies the proprietary AI-based drug discovery technology for building its pipeline and strategic collaborations with the companies. The AI technology can be applied in any therapeutic area and allows advancing drug candidates into Phase 2a in less than one year (through 505b2 pathway). It also allows improving the effectiveness of drug discovery and drug life cycle management by the identification of novel targets and indications for the molecules.

Merck Sharp & Dohme Corp. engages in the research, development, and distribution of vaccines, prescription drugs, and animal health products. The company is headquartered in Whitehouse Station, NJ.

InnoTherapy, Inc. engages in the manufacture and sale of hemostatic medical agents. The company operates through the Absorbable Hemostat and Surgical Sealant. Its products include homeostatic agents, sealants and adhesives. The company was founded by Moon-Soo Lee and Hae-Shin Lee on April 19, 2010 and is headquartered in Seoul, South Korea.

Serina Therapeutics is a privately-held pharmaceutical company that is advancing novel therapeutics for cancer, inflammation, pain, and metabolic disorders using its proprietary polymer technology. They have created new pharmaceutical candidates using polyoxazoline (POZ), a safe, water-soluble polymer to which they can attach a variety of small molecules, proteins, peptides, and DNA. The attachment of these molecules to polymers of POZ typically confers a unique pharmacokinetic profile that is markedly different from the parent compound, and this profile may confer advantages in terms of safety and efficacy.

Neurocrine Biosciences engages in the discovery and development of drugs for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company develops drugs for endometriosis, anxiety, depression, pain, diabetes, irritable bowel syndrome, insomnia, and other neurological and endocrine related diseases and disorders. Its products in clinical development comprise Elagolix, a Phase II product for Endometriosis; CRF1 Antagonist, a phase II product for mood disorders; CRF2 Peptide Agonist, a phase II drug for Cardiovascular related diseases; CRF1 Antagonist, a Phase I product for treating Mood Disorders and Irritable Bowel Syndrome; and Elagolix, a Phase I product for treating Benign Prostatic Hyperplasia and Uterine Fibroids. The company's research programs include Vesicular Monoamine Transporter 2 Inhibitor for movement disorders and schizophrenia; Glucose Dependent Insulin Secretagogues for type II diabetes; Antiepileptic drugs for epilepsy and bipolar disorder; and GnRH Antagonists for hormone dependent diseases and oncology. It has strategic alliances with GlaxoSmithKline to develop and commercialize CRF antagonists for psychiatric, neurological, and gastrointestinal diseases; and Dainippon Sumitomo Pharma Co. Ltd. to develop and commercialize indiplon in Japan. Neurocrine Biosciences, Inc. was founded in 1992 and is based in San Diego, California.

Grünenthal GmbH engages in the research and development of pharmaceutical products. It specializes in pain, gout, and inflammation. The company was founded by Hermann Wirtz in 1946 and is headquartered in Aachen, Germany.

Metabolon is a technology company, develops analytical methods and software for biomarker discovery using metabolomics. It offers a biochemical profiling platform that analyzes and identifies biochemicals in the research of pharmaceutical, biotech, agriculture, cosmetic, and consumer products. Metabolon provides a unique, real-time fingerprint of biological system to reveal novel discoveries and realize the promise of precision medicine. The company can deliver an instantaneous snapshot of the entire physiology of a living being at a discreet point in time, as well as identify changes in that system brought about the impact of the disease, medical intervention, diet, or the environment. This deep and comprehensive view of the metabolome provides biological insights that cannot be revealed through any other research methodology, enabling life sciences researchers and drug developers to discover answers to some of biology’s most difficult questions. Metabolon was founded in 2000 and headquartered in Durham, North Carolina.

Orion World is a manufacturer of Orion Caramel and localized drops called Orion King Drops with four flavors, orange, pineapple, strawberry, and lemon. The company was established in 1956 by Lee Yang-Gu and is based in Seoul, Korea.

Orion Oyj develops, manufactures, and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients. It specializes in central nervous system disorders, oncology, and respiratory diseases. The firm's customers are specialist and general practitioners, veterinarians, pharmacies, hospitals, healthcare centers, clinics, and laboratories. The company was founded by Onni Turpeinen, Eemil Tuurala and Wikki Valkama on September 21, 1917 and is headquartered in Espoo, Finland.

Part of amana, Inc., Orion Co., Ltd. is a Japanese company located in Tokyo. The firm provides photos, computer graphics and related visual content. On December 28, 2005 amana, Inc. acquired Orion Co., Ltd. for $3.59 million.

UMC Utrecht Holding BV engages in utilization and commercialization of academic researches. It offers research support and training services. The company was founded in 1996 and is headquartered in Utrecht, the Netherlands.

Sentryx BV is a Dutch company located in Austerlitz. The firm operates as orthopedic surgeon. It was founded by Bas Oosterman and Jorrit-Jan Verlaan. Bas Oosterman is the current CEO of the firm.\nThe company says this about itself: SentryX is a life sciences company based in Utrecht, the Netherlands, that develops next-generation pain relief therapeutics. SentryX was founded by Prof. dr. J.J. Verlaan and Dr. B.J. Oosterman and spun out of the University Medical Center Utrecht, the Netherlands.

Kissei Pharmaceutical Co., Ltd. engages in the research, development, manufacture and sale of pharmaceutical products and health foods. It operates through the following segments: Pharmaceuticals, Information Service, and Others. The Pharmaceuticals segment researches, develops, manufactures, and markets drugs, which are used in the fields of urology, dialysis, women's health, ophthalmology, endocrinology and metabolism. The Information Service segment offers information services to use in IT and capital investment. The Others segment includes merchandise sales and construction contractors. The company was founded on August 9, 1946 and is headquartered in Matsumoto, Japan.

Nanjing Renwei Pharmaceutical Technology Co., Ltd., established on 2014-01-08, Business scope includes technical development of pharmaceutical products,technology transfer,technical consulting;Technology development of biotechnology and products,technology transfer,technical consulting;Chemical Products(Does not contain dangerous goods),chemical reagent,Technology development of pharmaceutical intermediates,technology transfer,technical consulting,Sales;Office Supplies,household appliances,Communication equipment,Instrumentation,Wire and Cable,building decoration materials,Computer hardware and software,clothing,crafts,Sales of daily necessities.(Except for licensed items)(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments) General project:Sales of daily chemical products(Except for projects subject to approval by law,Carry out business activities independently in accordance with the law with a business license)